vatalanib has been researched along with Angiogenesis, Pathologic in 67 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 49 (73.13) | 29.6817 |
| 2010's | 16 (23.88) | 24.3611 |
| 2020's | 2 (2.99) | 2.80 |
| Authors | Studies |
|---|---|
| Acemoglu, F; Altmann, KH; Bold, G; Boss, E; Brüggen, J; Buchdunger, E; Cozens, R; Emmenegger, R; Ferrari, S; Frei, J; Furet, P; Hofmann, F; Lang, M; Lässer, L; Manley, PW; Martiny-Baron, G; Masso, E; Mestan, J; Rösel, J; Roth, R; Schlachter, C; Sills, M; Stover, D; Traxler, P; Vetterli, W; Wietfeld, B | 1 |
| Aono, H; Ban, M; Honda, T; Inaba, T; Inoue, K; Kawashima, K; Okamoto, K; Sasabuchi, Y; Tajima, H; Takeno, Y; Tonouchi, A; Tsuboi, T; Yamamoto, M | 1 |
| Chang, SM; Chen, TL; Huang, JR; Jain, V; Lee, TC; Lin, YW; Patel, AS; Pidugu, HB; Shah, A; Su, TL; Wu, HC; Wu, MH | 1 |
| Chen, TL; Hou, MH; Jain, V; Kuppusamy, R; Lee, TC; Lin, YW; Patel, AS; Su, TL | 1 |
| Bennewitz, K; Hammes, HP; Hillebrands, JL; Krenning, G; Kroll, J; Metzger, L; Poschet, G; Qi, H; Stoll, SJ; Wiggenhauser, LM | 1 |
| Chen, L; Dasa, SSK; French, BA; Jansson-Löfmark, R; Kelly, KA; Klibanov, AL; Lindfors, L; Michaëlsson, E; Mugler, E; Suzuki, R | 1 |
| Achyut, BR; Angara, K; Ara, R; Arbab, AS; Bollag, RJ; Borin, TF; Iskander, A; Lebedyeva, I; Lin, PC; Rashid, MH | 1 |
| Bold, G; Breier, G; Buchdunger, E; Diermeier-Daucher, S; Drexler, HC; Gaumann, AK; Lang, SA; Stoeltzing, O; Wood, J | 1 |
| Achyut, BR; Angara, K; Ara, R; Arbab, AS; Borin, TF; Iskander, A; Jain, M; Rashid, MH; Shankar, A | 1 |
| Alsop, DC; de Bazelaire, C; George, D; Michaelson, MD; Pedrosa, I; Rofsky, NM; Wang, Y | 1 |
| Baum, O; Djonov, V; Gruber, G; Hlushchuk, R; Pruschy, M; Riesterer, O; Wood, J | 1 |
| Cordeiro, MM; Dong, Z; Miyazawa, M; Neiva, KG; Nör, JE; Oliveira, DT; Zhang, Z | 1 |
| Antoniadis, H; Christofori, G; Crnic, I; Littlewood-Evans, A; Schomber, T; Strittmatter, K; Wood, J; Zumsteg, A | 1 |
| Allegrini, PR; Boulay, A; Brueggen, J; Lane, HA; Littlewood-Evans, A; Maira, SM; Martiny-Baron, G; McSheehy, PM; O'Reilly, T; Schnell, CR; Sini, P; Wood, JM | 1 |
| Barbarroja, N; Carretero, RM; López-Pedrera, C; Lopez-Sanchez, LM; Luque, MJ; Rodriguez-Ariza, A; Torres, A; Torres, LA; Valverde-Estepa, A; Velasco, F | 1 |
| Arnold, D; Grothey, AA; Haerting, J; Unverzagt, S; Wagner, AD | 1 |
| Cejka, D; Fuereder, T; Hoeflmayer, D; Jaeger-Lansky, A; Koehrer, S; Preusser, M; Wacheck, V; Ying, L | 1 |
| A'Hern, R; Banerjee, S; Detre, S; Dowsett, M; Evans, DB; Littlewood-Evans, AJ; Martin, LA | 1 |
| Liu, JM; Tang, GS; Wang, Y; Yue, ZJ; Zhang, H; Zhang, YH | 1 |
| Djonov, V; Hlushchuk, R; Huynh-Do, U; Tuffin, G; Wnuk, M | 1 |
| Böhm-Sturm, P; Diedenhofen, M; Hoehn, M; Jikeli, JF; Ullrich, RT; Unruh, M; Vollmar, S | 1 |
| Broggini-Tenzer, A; Jochum, W; Oehler-Jänne, C; Pruschy, M; Riesterer, O; Vuong, V | 1 |
| Anderson, KC; Podar, K | 1 |
| Döme, B; Török, S | 1 |
| Azuma, M; Danenberg, KD; Danenberg, PV; Folprecht, G; Ladner, RD; Lebwohl, D; Lenz, HJ; Meinhardt, G; Sherrod, A; Shi, MM; Trarbach, T; Wilson, PM; Yang, D; Zhang, W | 1 |
| Folprecht, G; Gatter, KC; Giatromanolaki, A; Harris, AL; Jalava, T; Koukourakis, MI; Laurent, D; Lebwohl, D; Meinhardt, G; Shi, MM; Sivridis, E; Trarbach, T | 1 |
| Allegrini, PR; Drevs, J; Esser, N; Fuxius, S; Hennig, J; Hugenschmidt, H; Konerding, MA; Marmé, D; Müller-Driver, R; Unger, C; Wittig, C; Wood, J | 1 |
| Rosen, LS | 1 |
| Fan, TP; Gherardi, E; Sasisekharan, R; Sellers, LA; Sengupta, S; Wood, JM | 1 |
| Brasch, RC; Carter, WO; Floyd, E; Fu, Y; Novikov, V; Preda, A; Roberts, TP; Shames, DM; Turetschek, K; Wood, JM | 1 |
| Durrance, A; Erlich, R | 1 |
| Eilles, C; Grimm, D; Infanger, M; Kossmehl, P; Kurth, E; Schoenberger, J | 1 |
| Huang, S; Kim, LS; Lev, DC; Lu, W; Price, JE | 1 |
| Bendszus, M; Goldbrunner, RH; Kiderlen, M; Sasaki, M; Tonn, JC; Wood, J | 1 |
| Kiziltepe, T; Sasisekharan, R; Sengupta, S | 1 |
| Atadja, P; Kachhap, SK; Kato, Y; Pili, R; Qian, DZ; Wang, X; Wei, Y; Zhang, L | 1 |
| Bilenker, JH; Haller, DG | 1 |
| Goldberg, RM; Penland, SK | 1 |
| Doherty, M | 1 |
| Collins, TS; Hurwitz, HI | 1 |
| Fan, ST; Kok, TW; Lau, C; Li, Q; Liu, Y; Poon, RT | 1 |
| Herbst, RS; Onn, A; Sandler, A | 1 |
| Allegrini, PR; Baumann, D; Becquet, M; Brecht, K; Brueggen, J; Ferretti, S; McSheehy, PM; Rausch, M; Rudin, M; Schaeffer, F; Schnell, C; Wood, J | 1 |
| Drevs, J; Günther, C; Hennig, J; Ho, YY; Laurent, D; Lebwohl, D; Marmé, D; Masson, E; Medinger, M; Morgan, B; Mross, K; Müller, M; Unger, C | 1 |
| Baumann, M; Dörfler, A; Eicheler, W; Geyer, P; Haberey, M; Hessel, F; Thames, HD; Zips, D | 1 |
| Schiller, JH; Wakelee, HA | 1 |
| Soff, G; Zakarija, A | 1 |
| Agarwala, SS; Tawbi, H | 1 |
| Bucana, CD; Carter, KB; Jasser, SA; Kim, S; Myers, JN; Wang, Z; Yazici, YD | 1 |
| Billy, E; Butler, J; Hla, T; LaMontagne, K; Liau, G; Littlewood-Evans, A; O'Reilly, T; Probst, B; Sanchez, T; Schnell, C; Theuer, A; Wood, A; Wood, J; Wyder, L | 1 |
| Ametamey, S; Honer, M; Jochum, W; Oehler, C; Pruschy, M; Riesterer, O | 1 |
| Arevalo, JM; Armaiz-Pena, G; Bankson, JA; Cole, SW; Coleman, RL; Felix, E; Gershenson, DM; Han, LY; Jennings, NB; Kamat, AA; Kim, TJ; Kundra, V; Landen, CN; Li, Y; Lin, YG; Lloyd, M; Lopez-Berestein, G; Lu, C; Lutgendorf, SK; Mangala, LS; Merritt, WM; Newman, RA; Ravoori, M; Sanguino, AM; Sood, AK; Takahashi, R; Thaker, PH | 1 |
| Fan, ST; Ho, DW; Lam, CT; Lau, CK; Liu, Y; Poon, RT; Tam, KH; Yang, ZF | 1 |
| Colgan, SM; Major, P; Mukherjee, S | 1 |
| Armand, JP; Mir, O; Ropert, S | 1 |
| Abbas, F; André, T; de Gramont, A; Louvet, C; Tournigand, C | 1 |
| Casado, E; Cortés, J; Prat, A | 1 |
| Lee, CB; Socinski, MA | 1 |
| Campochiaro, PA; Hofmann, F; Okamoto, N; Ozaki, H; Ozaki, K; Seo, MS; Wood, JM; Yamada, E; Yamada, H | 1 |
| Fidler, IJ; Herrera, C; Killion, JJ; Wood, J; Xu, L; Yoneda, J | 1 |
| Bucana, CD; Fidler, IJ; Herbst, RS; Killion, JJ; Knighton, B; Shinohara, H; Wood, J; Yano, S | 1 |
| Bold, G; Buchdunger, E; Cozens, R; Drevs, J; Ferrari, S; Frei, J; Hofmann, F; Martiny-Baron, G; Menrad, A; Mestan, J; Mett, H; O'Reilly, T; Persohn, E; Rösel, J; Schirner, M; Schneider, MR; Schnell, C; Siemeister, G; Stover, D; Theuer, A; Thierauch, KH; Totzke, F; Towbin, H; Wenger, F; Wood, JM; Woods-Cook, K | 1 |
| Drevs, J; Hofmann, I; Hugenschmidt, H; Madjar, H; Marmé, D; Martiny-Baron, G; Müller, M; Unger, C; Wittig, C; Wood, J | 1 |
| Wood, JM | 1 |
| Bodis, S; Fabbro, D; Glanzmann, C; Hegyi, I; Hess, C; Pruschy, M; Riesterer, O; Vuong, V; Wood, J | 1 |
| Baker, CH; Fidler, IJ; Solorzano, CC | 1 |
16 review(s) available for vatalanib and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Anti-angiogenic therapies for metastatic colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Combined Modality Therapy; Disease-Free Survival; Humans; Neovascularization, Pathologic; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2009 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Inhibitors of the vascular endothelial growth factor receptor.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Colorectal Neoplasms; Drug Design; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Enzyme Inhibitors; Humans; Indoles; Intercellular Signaling Peptides and Proteins; Lymphokines; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Phthalazines; Piperidines; Pyridines; Pyrroles; Quinazolines; Recombinant Proteins; RNA, Catalytic; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2002 |
Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors.
Topics: Angiogenesis Inhibitors; Clinical Trials, Phase I as Topic; Female; Humans; Indoles; Lung Neoplasms; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Phthalazines; Prognosis; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sunitinib; Treatment Outcome | 2004 |
Future directions with angiogenesis inhibitors in colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Disease Models, Animal; Drug Approval; Forecasting; Humans; Neovascularization, Pathologic; Phthalazines; Prognosis; Pyridines; Risk Assessment; Survival Analysis; Treatment Outcome; United States; United States Food and Drug Administration | 2004 |
Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Organoplatinum Compounds; Phthalazines; Pyridines; Risk Assessment; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2004 |
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Celecoxib; Colorectal Neoplasms; Humans; Neovascularization, Pathologic; Phthalazines; Pyrazoles; Pyridines; RNA, Catalytic; Sulfonamides; Thalidomide; Vascular Endothelial Growth Factors | 2005 |
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2005 |
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
Topics: Benzenesulfonates; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2005 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
Hypoxia-induced lactate dehydrogenase expression and tumor angiogenesis.
Topics: Colorectal Neoplasms; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; L-Lactate Dehydrogenase; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
[Anti-angiogenic treatment and colorectal cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Hypertension; Intestinal Perforation; Neovascularization, Pathologic; Phthalazines; Pyridines; Thromboembolism; Vascular Endothelial Growth Factor A; Wound Healing | 2007 |
New approaches in angiogenic targeting for colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Colorectal Neoplasms; Humans; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
4 trial(s) available for vatalanib and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Feasibility Studies; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Neovascularization, Pathologic; Phthalazines; Pyridines; Regional Blood Flow | 2008 |
Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leucovorin; Male; Middle Aged; Neovascularization, Pathologic; Organoplatinum Compounds; Phthalazines; Pyridines; RNA, Messenger; Transcriptome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Vascular density analysis in colorectal cancer patients treated with vatalanib (PTK787/ZK222584) in the randomised CONFIRM trials.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Endothelial Cells; Female; Humans; Immunohistochemistry; Male; Middle Aged; Neovascularization, Pathologic; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Predictive Value of Tests; Prognosis; Pyridines; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Ultrasonography, Doppler, Color | 2005 |
47 other study(ies) available for vatalanib and Angiogenesis, Pathologic
| Article | Year |
|---|---|
New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.
Topics: Administration, Oral; Angiogenesis Inhibitors; Aniline Compounds; Animals; Biological Availability; Cell Line; CHO Cells; Cricetinae; Enzyme Inhibitors; Humans; Mice; Models, Molecular; Neoplasms; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Proto-Oncogene Proteins; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Structure-Activity Relationship; Transfection; Vascular Endothelial Growth Factor Receptor-1 | 2000 |
Pyridylmethylthio derivatives as VEGF inhibitors: part 2.
Topics: Angiogenesis Inhibitors; Animals; Arthritis, Rheumatoid; Cells, Cultured; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Pyridines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2011 |
Design and Synthesis of 1,2-Bis(hydroxymethyl)pyrrolo[2,1- a]phthalazine Hybrids as Potent Anticancer Agents that Inhibit Angiogenesis and Induce DNA Interstrand Cross-links.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Damage; Humans; Mice; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2019 |
Discovery of Oral Anticancer 1,2-Bis(hydroxymethyl)benzo[
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Design; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasms, Squamous Cell; Neovascularization, Pathologic; Phthalazines; Small Cell Lung Carcinoma; Structure-Activity Relationship; Xenograft Model Antitumor Assays | 2021 |
Activation of Retinal Angiogenesis in Hyperglycemic
Topics: Animals; Blood Glucose; CRISPR-Cas Systems; Gene Deletion; Gene Expression Regulation; Homeodomain Proteins; Hyperglycemia; Larva; Neovascularization, Pathologic; Nitric Oxide; Phthalazines; Protein Kinase Inhibitors; Pyridines; Retinal Neovascularization; Retinal Vessels; Trans-Activators; Vascular Endothelial Growth Factor A; Zebrafish | 2020 |
Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs.
Topics: Animals; Drug Delivery Systems; Liposomes; Mice; Myocardial Infarction; Neovascularization, Pathologic; Peptide Library; Peptides; Phthalazines; Protein Kinase Inhibitors; Pyridines; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
CXCR2-Expressing Tumor Cells Drive Vascular Mimicry in Antiangiogenic Therapy-Resistant Glioblastoma.
Topics: Angiogenesis Inhibitors; Animals; Bevacizumab; Brain Neoplasms; Glioblastoma; Humans; Interleukin-8; Molecular Targeted Therapy; Neovascularization, Pathologic; Phenylurea Compounds; Phthalazines; Pyridines; Rats, Nude; Receptors, Interleukin-8B; Tissue Array Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).
Topics: Angiogenesis Inhibitors; Becaplermin; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Leiomyosarcoma; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
Vascular mimicry in glioblastoma following anti-angiogenic and anti-20-HETE therapies.
Topics: Amidines; Angiogenesis Inhibitors; Animals; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Nude | 2017 |
Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation.
Topics: Actins; Animals; Antineoplastic Agents; Cell Proliferation; Immunohistochemistry; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Necrosis; Neovascularization, Pathologic; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Radiation, Ionizing; Time Factors; Tissue Survival; Up-Regulation; Xenograft Model Antitumor Assays | 2008 |
Effect of PTK/ZK on the angiogenic switch in head and neck tumors.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Coculture Techniques; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Vascular; Head and Neck Neoplasms; Humans; Interleukin-8; Mice; Mice, SCID; Microvessels; Neoplasm Transplantation; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Disease Progression; Lymphangiogenesis; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor | 2009 |
mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Cell Movement; Cell Proliferation; Everolimus; Female; Humans; Immunoenzyme Techniques; Magnetic Resonance Imaging; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Rats; Rats, Inbred BN; Rats, Inbred WF; Receptor, TIE-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Tissue Distribution; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2009 |
Additive effect of PTK787/ZK 222584, a potent inhibitor of VEGFR phosphorylation, with Idarubicin in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2009 |
Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Everolimus; Humans; Immunosuppressive Agents; Mice; Mice, Nude; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Stomach Neoplasms; TOR Serine-Threonine Kinases; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2010 |
Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Aromatase; Aromatase Inhibitors; Cell Line, Tumor; Cell Proliferation; Female; Humans; Immunohistochemistry; Letrozole; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neovascularization, Pathologic; Nitriles; Phthalazines; Pyridines; Receptors, Estrogen; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazoles; Xenograft Model Antitumor Assays | 2010 |
Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Disease Models, Animal; Drug Delivery Systems; Glioma; Humans; Lactic Acid; Male; Neovascularization, Pathologic; Phthalazines; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pyridines; Rats; Rats, Sprague-Dawley; Temozolomide; Treatment Outcome | 2010 |
The effects of PTK787/ZK222584, an inhibitor of VEGFR and PDGFRβ pathways, on intussusceptive angiogenesis and glomerular recovery from Thy1.1 nephritis.
Topics: Actins; Animals; Glomerular Filtration Rate; Kidney; Kidney Glomerulus; Male; Microfilament Proteins; Microscopy, Confocal; Neovascularization, Pathologic; Nephritis; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Wistar; Receptor, Platelet-Derived Growth Factor beta; Tensins; Vascular Endothelial Growth Factor Receptor-1 | 2011 |
In-vivo visualization of tumor microvessel density and response to anti-angiogenic treatment by high resolution MRI in mice.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Magnetic Resonance Imaging; Mice; Microvessels; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Xenograft Model Antitumor Assays | 2011 |
Ionizing radiation and inhibition of angiogenesis in a spontaneous mammary carcinoma and in a syngenic heterotopic allograft tumor model: a comparative study.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma; Female; Humans; Male; Mammary Neoplasms, Animal; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Phthalazines; Pyridines; Radiation, Ionizing; Receptors, Vascular Endothelial Growth Factor; Transplantation, Homologous | 2011 |
PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging.
Topics: Angiogenesis Inhibitors; Animals; Benzimidazoles; Blood Vessels; Capillary Permeability; Carcinoma, Renal Cell; Enzyme Inhibitors; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorescent Dyes; Heterocyclic Compounds; Kidney Neoplasms; Magnetic Resonance Angiography; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow | 2002 |
Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor.
Topics: Animals; Cell Division; Cells, Cultured; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Transfection; Tumor Cells, Cultured; Umbilical Veins; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model.
Topics: Angiogenesis Inhibitors; Animals; Breast Neoplasms; Endothelium, Vascular; Female; Humans; Magnetic Resonance Imaging; Neoplasm Transplantation; Neovascularization, Pathologic; Phthalazines; Predictive Value of Tests; Pyridines; Rats; Treatment Outcome | 2003 |
American Society of Clinical Oncology-39th Annual Meeting. Angiogenesis. 31 May-3 June 2003, Chicago, IL, USA.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Humans; Neoplasms; Neovascularization, Pathologic; Oligopeptides; Phthalazines; Pyridines | 2003 |
Effects of PTK787/ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study.
Topics: Adenocarcinoma, Follicular; Angiogenesis Inhibitors; Animals; Cell Differentiation; Cell Line, Tumor; Extracellular Matrix Proteins; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Phthalazines; Protein-Tyrosine Kinases; Pyridines; Thyroglobulin; Thyroid Neoplasms; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Carcinoma, Ductal; Carotid Artery, Internal; Cell Hypoxia; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Injections, Intra-Arterial; Interleukin-8; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization.
Topics: Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Cell Division; Cell Survival; Glioma; Male; Neoplasm Transplantation; Neovascularization, Pathologic; Phthalazines; Pyridines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Transfection; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2004 |
A dual-color fluorescence imaging-based system for the dissection of antiangiogenic and chemotherapeutic activity of molecules.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Bibenzyls; Cell Line, Tumor; Coculture Techniques; Doxorubicin; Extracellular Matrix; Fluorescence; Hepatocyte Growth Factor; Humans; Melanoma; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Stilbenes; Thalidomide; Vascular Endothelial Growth Factor A | 2004 |
The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cattle; Cell Division; Cell Line, Tumor; Drug Synergism; Endothelium, Vascular; Enzyme Inhibitors; Gene Expression Regulation; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Mice, Nude; Neovascularization, Pathologic; Phthalazines; Pyridines; Transcription Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
The fight against cancer: the next round.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Mice; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2004 |
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Carrier Proteins; Caspase 3; Caspases; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Extracellular Matrix Proteins; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myosin Heavy Chains; Neovascularization, Pathologic; Nonmuscle Myosin Type IIB; Phthalazines; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2005 |
PTK787/ZK222584, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Contrast Media; Female; Heterocyclic Compounds; Magnetic Resonance Imaging; Melanoma; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Organometallic Compounds; Phthalazines; Protein-Tyrosine Kinases; Pyridines; Vascular Endothelial Growth Factor A | 2005 |
Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
Topics: Animals; Blood Vessels; Carcinoma, Squamous Cell; Cell Growth Processes; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Humans; Hypopharyngeal Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2005 |
Targeted Therapies in Cancer - Fourth International Congress. Angiogenesis inhibition.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Humans; Neoplasms; Neovascularization, Pathologic; Phthalazines; Pyridines; Quinazolines; Vascular Endothelial Growth Factor A | 2005 |
Antivascular therapy of oral tongue squamous cell carcinoma with PTK787.
Topics: Animals; Camptothecin; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Therapy, Combination; Follow-Up Studies; In Vitro Techniques; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Prodrugs; Protein Kinase Inhibitors; Pyridines; Tongue Neoplasms; Treatment Outcome | 2005 |
Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
Topics: Animals; Calcium; Cell Growth Processes; Cell Movement; Cornea; Endothelial Cells; Female; Fingolimod Hydrochloride; Humans; Melanoma, Experimental; Mice; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Neovascularization, Physiologic; Phosphorylation; Phthalazines; Propylene Glycols; Pyridines; Receptors, Lysosphingolipid; Sphingosine; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Ionizing radiation antagonizes tumor hypoxia induced by antiangiogenic treatment.
Topics: Animals; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Screening Assays, Antitumor; Glucose Transporter Type 1; Humans; Immunohistochemistry; Mammary Neoplasms, Animal; Mice; Misonidazole; Neoplasm Transplantation; Neovascularization, Pathologic; Phthalazines; Positron-Emission Tomography; Pyridines; Transplantation, Homologous | 2006 |
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma.
Topics: Animals; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Combinations; Enzyme Inhibitors; Female; Humans; Isoproterenol; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Organ Size; Ovarian Neoplasms; Phthalazines; Pyridines; Radiography; Random Allocation; Stress, Psychological; Terbutaline; Transplantation, Heterologous; Tumor Burden; Vascular Endothelial Growth Factor A | 2006 |
High doses of tyrosine kinase inhibitor PTK787 enhance the efficacy of ischemic hypoxia for the treatment of hepatocellular carcinoma: dual effects on cancer cell and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Endothelial Cells; Liver Neoplasms, Experimental; Male; Mice; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats; Rats, Inbred BUF; Vascular Endothelial Growth Factor A | 2006 |
Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization.
Topics: Aging; Angiogenesis Inhibitors; Animals; Animals, Newborn; Endothelial Growth Factors; Enzyme Inhibitors; Ischemia; Lymphokines; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Phosphotransferases; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Retinal Vessels; Rhodopsin; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Ascites; Capillary Permeability; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured | 2000 |
Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Capillary Permeability; Cell Division; Cell Line; Endothelial Growth Factors; Endothelium, Vascular; Gene Expression Regulation; Humans; Immunohistochemistry; In Situ Hybridization; Lung Neoplasms; Lymphokines; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Pleural Effusion, Malignant; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Cells; Carcinoma; Cell Division; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Hematopoiesis; Humans; Kidney Neoplasms; Leukocytes; Lymphokines; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Platelet-Derived Growth Factor; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wound Healing | 2000 |
Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Carcinoma, Renal Cell; Cell Division; Cyclohexanes; Disease Models, Animal; Enzyme Inhibitors; Female; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Renal Circulation; Sesquiterpenes | 2000 |
Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Topics: Angiogenesis Inhibitors; Animals; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Endothelium, Vascular; Humans; Lymphokines; Mice; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Phthalazines; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2000 |
Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth.
Topics: Adenocarcinoma; Administration, Oral; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Division; Colonic Neoplasms; Combined Modality Therapy; Endothelium, Vascular; Enzyme Inhibitors; Humans; Mice; Mice, Nude; Neoplasm Proteins; Neovascularization, Pathologic; Phthalazines; Protein-Tyrosine Kinases; Pyridines; Radiotherapy, Adjuvant; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2001 |
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phthalazines; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2002 |